Safe & Green Holdings Corp. (Nasdaq: SGBX) — FY2023 Form 10-K
Entity note: The filing is for Safe & Green Holdings Corp., not Olenox Industries Inc. It reports the fiscal year ended December 31, 2023; the filing does not provide a standalone fourth-quarter summary. Share and per-share amounts were retroactively adjusted for the May 2, 2024 1-for-20 reverse split.
Business context
The company manufactures modular building products and provides construction services. It also reports medical, real estate development and environmental activities. In September 2023, it distributed approximately 30% of Safe and Green Development Corporation (SG DevCorp) to shareholders; SGBX retained approximately 70% and continued consolidating SG DevCorp. Medical testing revenue ended after the COVID-19 joint venture wound down in 2022. SG Medical and SG Environmental had not generated revenue by year-end 2023.
Key financial results
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $16.52 million | $24.39 million |
| Gross profit (loss) | $(2.56) million | $3.25 million |
| Gross margin | Approximately (15.5)% | Approximately 13.3% |
| Operating loss | $(24.77) million | $(7.23) million |
| Net loss | $(26.76) million | $(7.09) million |
| Net loss attributable to SGBX common stockholders | $(26.28) million | $(8.32) million |
| Cash used in operating activities | $(7.14) million | $(5.63) million |
| Cash and cash equivalents at year-end | $17,448 | $582,776 |
Construction revenue rose 30% to $16.52 million, but the loss in that segment widened to $2.72 million. Medical revenue fell to zero from $11.64 million. One customer accounted for approximately 87% of 2023 revenue, versus 65% in 2022; three customers represented all gross receivables at year-end.
At December 31, 2023, total assets were $17.21 million, total liabilities $23.55 million, and stockholders’ equity was negative $6.33 million. Current assets of $5.34 million were substantially below current liabilities of $20.55 million; the company reported negative working capital of approximately $15.21 million. Cash flow from financing was $7.44 million, primarily reflecting borrowing, while investing activities used $0.86 million.
Material changes and unusual items
- Revenue declined 32%, principally because medical testing revenue ceased. Construction revenue growth did not offset the loss of medical activity.
- Construction costs exceeded construction revenue. Management cited higher materials costs and recorded approximately $871,000 of accrued construction losses.
- Operating expenses included a $5.98 million impairment charge; the filing also reports goodwill was fully impaired and describes impairment of intangible assets and other assets. The financial statements report total impairment loss of $5.98 million.
- Interest expense rose to $2.61 million from $0.34 million, reflecting additional borrowing. The company’s financing included a secured note bearing 23% annual interest, merchant cash advances with frequent receivable withdrawals, and convertible debt.
- Backlog fell to $1.90 million from $6.81 million. The company expected the year-end backlog to convert within one year, but contracts may be cancelled, deferred or changed.
- The company recorded $450,000 of legal settlement income in 2023. It also wrote off notes receivable, including $750,000 principal and accrued interest, and disclosed bad-debt expense.
Liquidity, outlook and risks
The independent auditor issued an unqualified opinion on the 2023 financial statements but highlighted substantial doubt about the company’s ability to continue as a going concern. The company reported recurring losses, negative working capital, negative operating cash flow and only $17,448 of cash at year-end. Management said it would seek increased revenue, expense reductions and additional debt or equity funding, but disclosed no secured additional funding source sufficient to resolve the shortfall. No formal revenue or earnings guidance is provided.
Subsequent financing disclosures reinforce the liquidity and dilution risks: the company entered into additional cash advances and convertible debt after year-end, and disclosed a planned May 2024 equity and warrant offering expected to raise approximately $4.0 million gross, subject to closing conditions. The company also disclosed a March 2024 workforce reduction at SG Echo, with some employees expected to return in April.
- Debt and collateral: Much of the borrowing is short-term, high-cost or secured by company assets and receivables. SGBX guaranteed SG Echo obligations under the SouthStar arrangements, which include cross-default and cross-collateralization provisions.
- Customer and execution concentration: Revenue dependence on one customer, a reduced backlog, project cost overruns and the fixed costs of manufacturing create material earnings volatility.
- Shareholder dilution and listing: Convertible securities, warrants, equity purchase arrangements and subsequent issuances may substantially dilute existing holders. Nasdaq had notified SGBX of a minimum-bid-price deficiency; the company effected a reverse split in May 2024.
- Controls and legal matters: Management concluded internal control over financial reporting was not effective, citing insufficient accounting resources and weaknesses in the close process and complex-transaction accounting. The filing also describes ongoing litigation for which some potential losses cannot be estimated.
Important facts for investors to verify
- Current cash, available borrowing capacity, weekly cash-advance deductions, debt maturities and the company’s ability to meet near-term obligations.
- Whether the disclosed post-year-end financings and planned offering closed, their net proceeds, and the resulting fully diluted share count.
- Whether the company regained and continues to satisfy Nasdaq listing requirements after the reverse split.
- Whether the $1.90 million backlog converts to revenue and whether projects can be completed without further losses or additional working capital.
- Customer concentration, receivable collections and the status of the company’s material litigation and internal-control remediation.